Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus‐coinfected patients receiving sofosbuvir‐based direct‐acting antivirals and antiretroviral therapy

• Published in: Journal of viral hepatitis 2021-06, Vol.28 (6), p.887-896
• Main Authors: Liu, Chen‐Hua, Sun, Hsin‐Yun, Hsieh, Szu‐Min, Liu, Wen‐Chun, Sheng, Wang‐Hui, Liu, Chun‐Jen, Su, Tung‐Hung, Tseng, Tai‐Chung, Chen, Pei‐Jer, Hung, Chien‐Ching, Kao, Jia‐Horng
• Format: Article
• Language: English
• Subjects: Antiretroviral drugs; Antiretroviral therapy; Antiviral agents; Drug therapy; Epidemiology; Epidermal growth factor receptors; estimated glomerular filtration rate; Glomerular filtration rate; Hepatitis; Hepatitis C; hepatitis C virus; HIV; Human immunodeficiency virus; Kidney diseases; sofosbuvir; Tenofovir; Viruses
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.13502

The nephrotoxicity of sofosbuvir (SOF) on human immunodeficiency virus and hepatitis C virus (HIV/HCV)‐coinfected patients receiving antiretroviral therapy (ART) remains controversial. We prospectively compared the estimated glomerular filtration rate (eGFR) changes in 167 patients receiving SOF‐based direct‐acting antivirals (DAAs) who also received tenofovir disoproxil fumarate (TFV)‐based (n = 116) and TFV‐free ART (n = 51). The eGFR was assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation, and the eGFR changes between ART regimens were compared by the generalized estimated equation. During DAA treatment, participants on TFV‐based ART had a higher eGFR decline than those on TFV‐free ART (slope coefficient difference: −0.82 ml/min/1.73 m2/month [95% CI: −1.21 to −0.43]; p